Business Description
Kilitch Drugs (India) Ltd
ISIN : INE729D01010
Total Employee Number:
187Compare
Compare
Traded in other countries / regions
524500.India IPO Date
2010-09-29Description
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.78 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.32 | |||||
Debt-to-EBITDA | 1.85 | |||||
Interest Coverage | 5.93 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 3.29 | |||||
Beneish M-Score | -1.96 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.8 | |||||
3-Year EBITDA Growth Rate | 30 | |||||
3-Year EPS without NRI Growth Rate | 42.1 | |||||
3-Year FCF Growth Rate | -287 | |||||
3-Year Book Growth Rate | 18.9 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.98 | |||||
9-Day RSI | 43.9 | |||||
14-Day RSI | 48.38 | |||||
3-1 Month Momentum % | 27.64 | |||||
6-1 Month Momentum % | -0.86 | |||||
12-1 Month Momentum % | -19.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.83 | |||||
Quick Ratio | 1.73 | |||||
Cash Ratio | 0.57 | |||||
Days Inventory | 44.22 | |||||
Days Sales Outstanding | 153.88 | |||||
Days Payable | 168.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.2 | |||||
Shareholder Yield % | -14.19 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 46.12 | |||||
Operating Margin % | 14 | |||||
Net Margin % | 12.81 | |||||
EBITDA Margin % | 20.32 | |||||
FCF Margin % | -32.08 | |||||
OCF Margin % | 10.17 | |||||
ROE % | 12.1 | |||||
ROA % | 7.74 | |||||
ROIC % | 9.86 | |||||
3-Year ROIIC % | 8.4 | |||||
ROC (Joel Greenblatt) % | 21.74 | |||||
ROCE % | 15.07 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.69 | |||||
Forward PE Ratio | 24.73 | |||||
PE Ratio without NRI | 20.69 | |||||
Shiller PE Ratio | 45.46 | |||||
PEG Ratio | 0.49 | |||||
PS Ratio | 2.66 | |||||
PB Ratio | 2.3 | |||||
Price-to-Tangible-Book | 2.46 | |||||
Price-to-Operating-Cash-Flow | 26.01 | |||||
EV-to-EBIT | 14.76 | |||||
EV-to-EBITDA | 13.65 | |||||
EV-to-Revenue | 2.77 | |||||
EV-to-FCF | -8.99 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.83 | |||||
Price-to-Graham-Number | 1.5 | |||||
| Price-to-Net-Current-Asset-Value | 14.59 | |||||
Earnings Yield (Greenblatt) % | 6.77 | |||||
FCF Yield % | -11.89 | |||||
Forward Rate of Return (Yacktman) % | 17.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kilitch Drugs (India) Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 2,354.75 | ||
| EPS (TTM) (₹) | 8.895 | ||
| Beta | 1.5749 | ||
| 3-Year Sharpe Ratio | 0.61 | ||
| 3-Year Sortino Ratio | 1.05 | ||
| Volatility % | 52.25 | ||
| 14-Day RSI | 48.38 | ||
| 14-Day ATR (₹) | 9.778826 | ||
| 20-Day SMA (₹) | 188.334 | ||
| 12-1 Month Momentum % | -19.13 | ||
| 52-Week Range (₹) | 117.25 - 250 | ||
| Shares Outstanding (Mil) | 34.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kilitch Drugs (India) Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kilitch Drugs (India) Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 2:1 Stock Split | 2026-03-24 | 156.80 (-2.31%) |
Show
Entries
Kilitch Drugs (India) Ltd Frequently Asked Questions
What is Kilitch Drugs (India) Ltd(NSE:KILITCH)'s stock price today?
The current price of NSE:KILITCH is ₹183.12. The 52 week high of NSE:KILITCH is ₹250.00 and 52 week low is ₹117.25.
When is next earnings date of Kilitch Drugs (India) Ltd(NSE:KILITCH)?
The next earnings date of Kilitch Drugs (India) Ltd(NSE:KILITCH) is .
Does Kilitch Drugs (India) Ltd(NSE:KILITCH) pay dividends? If so, how much?
Kilitch Drugs (India) Ltd(NSE:KILITCH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Kilitch Drugs (India) Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers